Company profile for Sparian Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Sparian Biosciences is a clinical-stage CNS-focused biopharmaceutical company committed to developing novel, transformational therapies. Central nervous system diseases represent a primary unmet need, but there has been little innovation and development recently. Sparian was co-founded by Jeff Reich, MD, and Gavril Pasternak, MD PhD to develop therapeutics targeting the brain through innovative science and novel drug discovery...
Sparian Biosciences is a clinical-stage CNS-focused biopharmaceutical company committed to developing novel, transformational therapies. Central nervous system diseases represent a primary unmet need, but there has been little innovation and development recently. Sparian was co-founded by Jeff Reich, MD, and Gavril Pasternak, MD PhD to develop therapeutics targeting the brain through innovative science and novel drug discovery.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
180 Varick Street, New York, New York 10014-0121
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2024/11/14/2981367/0/en/Sparian-Biosciences-Awarded-19-5-Million-Five-Year-NIH-NIDA-Grant-to-Fund-Development-of-SBS-226-for-Opiate-Use-Disorder-Opiate-Withdrawal-Syndrome-Through-Phase-1-Clinical-Develop.html

GLOBENEWSWIRE
14 Nov 2024

https://www.globenewswire.com/news-release/2024/11/13/2980573/0/en/Sparian-Biosciences-Announces-Formation-of-its-Science-Advisory-Board.html

GLOBENEWSWIRE
13 Nov 2024

https://www.globenewswire.com/news-release/2024/11/12/2979419/0/en/Sparian-Biosciences-Announces-Results-from-the-Phase-1-Clinical-Trial-of-First-in-Class-Novel-Arylepoxamide-Receptor-AEAr-Agonist-Analgesic-SBS-1000.html

GLOBENEWSWIRE
12 Nov 2024

https://www.globenewswire.com/news-release/2023/08/08/2720562/0/en/Sparian-Biosciences-Awarded-19-Million-Five-Year-NIH-NIDA-Grant-to-Fund-Development-of-SBS-518-for-Stimulant-Use-Disorder-Through-Phase-1-Clinical-Development.html

GLOBENEWSWIRE
08 Aug 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty